Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 271 to 285 of 1003 results for public health medicine & health

  1. Tasimelteon for treating sleep disturbance associated with Smith-Magenis syndrome [TSID12191]

    Awaiting development Reference number: GID-TA11746 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Edaravone for treating amyotrophic lateral sclerosis [TSID11869]

    Awaiting development Reference number: GID-TA11362 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Pembrolizumab with chemoradiation for untreated high-risk advanced cervical cancer [TSID10690]

    Awaiting development Reference number: GID-TA11073 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Pembrolizumab with chemotherapy for adjuvant treatment of newly diagnosed high-risk endometrial cancer after surgery with curative intent [TSID11808]

    Awaiting development Reference number: GID-TA11200 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Botaretigene sparoparvovec for treating RPGR mutation-associated X-linked retinitis pigmentosa [ID6286]

    Awaiting development Reference number: GID-TA11332 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Rucaparib with nivolumab for maintenance treatment of platinum-sensitive advanced ovarian, fallopian tube or peritoneal cancer after 1 therapy [TSID10763]

    Awaiting development Reference number: GID-TA11048 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Rucaparib for treating hormone-relapsed metastatic prostate cancer with homologous recombination deficiency after 1 therapy [TSID10764]

    Awaiting development Reference number: GID-TA11049 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Prostate cancer (hormone relapsed, homologous recombination deficiency, metastatic) – rucaparib (after 1 therapy) [ID6127]

    Awaiting development Reference number: GID-TA11219 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Eneboparatide for treating chronic hypoparathyroidism [TSID12145]

    Awaiting development Reference number: GID-TA11713 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Golimumab biosimilar for Rheumatoid Arthritis, Juvenile Arthritis, Ankylosing Spondylitis, Axial Spondyloarthropathy, Psoriatic Arthritis, and Ulcerative Colitis [ID12208]

    Awaiting development Reference number: GID-TA11778 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Sabizabulin for treating COVID-19 [TSID11814]

    Awaiting development Reference number: GID-TA11226 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Vilobelimab for treating COVID-19 [TSID11815]

    Awaiting development Reference number: GID-TA11227 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Nedosiran treating primary hyperoxaluria type 1 in people 6 years and over [TSID11777]

    Awaiting development Reference number: GID-TA11292 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Sibeprenlimab for treating IgA nephropathy [ID6604]

    Awaiting development Reference number: GID-TA11668 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Atrasentan for treating primary IgA nephropathy [ID6558]

    Awaiting development Reference number: GID-TA11756 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development